A 52-year-old man with hypercholesterolaemia is started on atorvastatin (a competitive inhibitor of HMG-CoA reductase). His colleague is treated with a novel allosteric inhibitor of the same enzyme. Which laboratory finding would best distinguish the mechanism of action of these two drugs?

Explanation

## Distinguishing Competitive from Non-Competitive (Allosteric) Inhibition in Clinical Context ### The Atorvastatin Example **Key Point:** Atorvastatin is a **competitive inhibitor** of HMG-CoA reductase. It binds reversibly to the active site, directly competing with the natural substrate (HMG-CoA). **Clinical Pearl:** The competitive nature of atorvastatin's inhibition means that in cells with high HMG-CoA levels (e.g., during fasting or high-cholesterol diet), some substrate can still bind and be metabolized. This is why atorvastatin's effect is dose-dependent and can be partially overcome by substrate concentration. ### The Allosteric Inhibitor Comparison **Key Point:** An allosteric inhibitor binds to a regulatory site distinct from the active site. It cannot be overcome by increasing substrate concentration because it does not compete for substrate binding. **High-Yield:** The fundamental difference: - **Competitive:** Inhibitor vs. substrate compete for the same site → substrate can displace inhibitor - **Non-competitive/Allosteric:** Inhibitor binds elsewhere → substrate concentration is irrelevant to inhibitor binding ### Kinetic Mechanism Comparison ```mermaid flowchart TD A[HMG-CoA Reductase Inhibition]:::outcome --> B{Inhibitor binding site?}:::decision B -->|Active site| C[Competitive Inhibition]:::action B -->|Allosteric site| D[Non-Competitive Inhibition]:::action C --> E[High substrate overcomes inhibition]:::outcome D --> F[High substrate does NOT overcome inhibition]:::outcome E --> G[Atorvastatin mechanism]:::outcome F --> H[Novel allosteric inhibitor mechanism]:::outcome ``` ### Why This Matters in Drug Development **Mnemonic:** **SODA** = **S**ubstrate overcomes **O**nly **D**irect (competitive) **A**ctive-site inhibition. | Property | Atorvastatin (Competitive) | Allosteric Inhibitor | | --- | --- | --- | | **Binding site** | Active site (HMG-CoA site) | Allosteric/regulatory site | | **Overcome by ↑[HMG-CoA]?** | Yes, partially | No | | **Km change** | Increased | Unchanged | | **Vmax change** | Unchanged | Decreased | | **Reversibility** | Reversible | Reversible | | **Dose-response** | Sigmoidal, substrate-dependent | Hyperbolic, substrate-independent | ### Clinical Implication **Warning:** In cells with very high HMG-CoA flux (e.g., hepatocytes during lipogenesis), a competitive inhibitor like atorvastatin may be partially overcome. An allosteric inhibitor would maintain full inhibition regardless of substrate concentration — potentially a therapeutic advantage or disadvantage depending on the clinical context. [cite:Lehninger Principles of Biochemistry 7e Ch 6; Harrison 21e Ch 406]